Panic Disorder Market Towards US$ 12,621.61 Mn By 2030, A Comprehensive Analysis By Reports Insights
29 mai 2023 05h00 HE
|
REPORTSINSIGHTS CONSULTING PVT LTD
New York, May 29, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Reports Insights, the panic disorder market is poised for strong expansion and is expected to reach USD 12,621.61 Million...
[Latest] Global Acute Repetitive Seizures Market Size/Share Worth USD 11.5 Billion by 2030 at a 12% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
21 avr. 2023 09h30 HE
|
Custom Market Insights
Austin, TX, USA, April 21, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Acute Repetitive Seizures Market Size, Trends and Insights By Drug Type...
Chemical Planet Introduce A Sample Pack Of Its 10 Best Benzodiazepine Samples, Including Bromazolam, FANAX, And Fluetizolam, With A Total Of 90 Pellets
29 nov. 2022 09h00 HE
|
Chemical Planet
Utrecht, Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Chemical Planet is a progressive research chemical supply company that strives to become number 1 in the research chemical field. They have...
Illicit Benzodiazepine Overdose Trends Detected by Toxicology Investigators Consortium (ToxIC)
02 sept. 2021 11h49 HE
|
American College of Medical Toxicology
Phoenix, AZ, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Data gathered by ToxIC’s Fentanyl Analog Study was reported in the CDC’s August 27, 2021 Morbidity and Mortality Weekly Report (MMWR) “Notes from the...
Global Delirium Management Market Is Anticipated Grow at a CAGR of 5.6% from 2021 to 2030
02 août 2021 06h00 HE
|
Quince Market Insights
Pune, India, Aug. 02, 2021 (GLOBE NEWSWIRE) -- The global delirium management market is expected to value at USD 352.6 million in 2021 and is expected to grow at a CAGR of 5.6% during the forecast...
RespireRx Pharmaceuticals Inc. Announces $2 Million Funding Commitment Allowing Option Exercise with UWM Research Foundation, Inc. and Entry into a License Agreement for GABA(A) Receptor Allosteric Neuromodulator Intellectual Property
04 août 2020 08h45 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), has historically been and remains a leader in the research and...